A large number of active ingredients can benefit from liposomal packaging. Many approved active ingredients cause severe side effects when used systemically because they are not targeted, or they have to be dosed too high because they only circulate in the body for a short time. A liposomal formulation opens up new possibilities here. InnoMedica's technology platform can be used both for clinically established active ingredients and for new, customized substances such as RNA or proteins. Through targeted design adjustments, InnoMedica's liposomal nanoparticle can be specifically adapted to the properties of the disease and the affected tissue, as well as the transported active ingredient. There are virtually no limits to InnoMedica's product pipeline.
In der Onkologie entwickelt InnoMedica mit TLD-1 die bewährte Chemotherapie Doxorubicin weiter. Für die Vorbereitung auf die Marktzulassung liegt nebst der Indikation Brustkrebs ein besonderer Fokus auf der seltenen Krebsart Weichteilsarkom (STS). Durch InnoMedicas liposomale Formulierung sollen die ansonsten auftretenden und häufig nicht tolerierbaren Nebenwirkungen des bekannten Wirkstoffs verhindert werden. InnoMedicas Neurologie-Produkt TLN-1, das sich in der klinischen Entwicklung befindet, soll neurodegenerativen Erkrankungen wie Parkinson entgegenwirken, in dem InnoMedicas Transportsystem die Überwindung der Blut-Hirn-Schranke ermöglicht und so den Wirkstoff GM1 dem Hirn zuführt. Zudem entwickelt InnoMedica ein Produkt zur Kennzeichnung von Tumoren für eine präzisere chirurgische Entfernung (TLTrace) und arbeitet an der Weiterentwicklung einer weiteren breit eingesetzten Chemotherapie Docetaxel (TLTaxel).
Research
Preclinical
Clinical
The nanocarrier of InnoMedica's oncology product transports the already approved, highly effective active ingredient doxorubicin and is designed to prevent serious, sometimes irreversible side effects of this chemotherapy. The intelligent surface coating of the liposomal nanoparticle ensures minimal interaction of the active ingredient with healthy tissue. The longer blood circulation time protects the excretory organs as they have more time for the degradation process. As the liposomal nanocarrier of the preparation is particularly small, targeted penetration of the tumor tissue and thus a high level of drug accumulation in the tumor is ensured.
Thanks to the unique composition of the nanocarrier for InnoMedica's neurology product, the active ingredient GM1 ganglioside that is integrated into the membrane can cross the blood-brain barrier and unfold its neuroprotective and neuroregenerative effect in the brain. GM1 ganglioside is an important component of nerve cells and plays a central role in neuronal development, information transmission and storage, in repair mechanisms and in the release of neurotrophins (messenger substances that are essential for the survival and regeneration of nerve cells). As InnoMedica's nanocarrier crosses the blood-brain barrier, the brain is supplied with more GM1 to protect the nerve cells. As it is an endogenous substance, it is also well tolerated.
